BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Braveheart Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$19.21+0.50 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $142.19M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$10.79 (−35.97%)since Aug 7, 2026
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $142.19M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- -$12.96
- Diluted shares
- 7M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period